Enjoy complimentary customisation on priority with our Enterprise License!
The global celiac diseases drugs market size is estimated to grow by USD 701.59 million at a CAGR of 17.01% between 2022 and 2027.
Several government initiatives are driving the market by funding the research, improving awareness among the people, and by providing therapeutics at subsidized prices. Globally, government organizations and non-profit organizations are taking numerous initiatives to increase awareness of rare diseases, such as celiac disease. For instance, Celiac Diseases Foundation creates awareness regarding celiac diseases through May Celiac Disease Awareness Month to educate, advocate, and accelerate research for celiac disease. In addition, hospitals also take initiatives to create awareness regarding celiac diseases. For instance, Stanford Children's Health creates awareness through "Celebrating Celiac Disease Awareness Month" in May Month. Several other organizations, such as the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the University of Oxford and Health Economics Research Centre are taking initiatives to create awareness regarding celiac diseases. Therefore, such government initiatives will drive the growth of the global celiac diseases market during the forecast period.
Technavio has segmented the market into therapy, route of administration, and geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the first line treatment segment will be significant during the forecast period. For celiac disease, the first line of treatment includes treatments that are mainly associated with the prevention and cure of the disease. This segment included a gluten-free diet, which is now an available choice for the prevention of triggering immune responses leading to different clinical manifestations.
Get a glance at the market contribution of various segments View a PDF Sample
The first line segment was the largest and was valued at USD 307.17 million in 2017. The first line of treatment is presently dominated by a gluten-free diet as this is the only available option for the prevention of immune response. Furthermore, the current volume-driven market is expected to change into a value-driven market upon the successful launch of a few novel late-stage pipeline molecules. However, due to economic constraints, these new launches will find it challenging to penetrate the low economic regions, which could restrict market growth. Therefore, the segment is anticipated to experience significant growth, thereby fueling the growth of the market during the forecast period.
Oral routes of administration are becoming increasingly popular in the global celiac disease drug market due to their simplicity and patient compliance. Oral medicines have gained huge acceptance as an effective approach to controlling celiac disease, addressing symptoms, and lowering inflammation in the digestive tract. Further, in severe situations, oral immunosuppressants such as azathioprine (Imuran) may be administered to control the immunological response. Such a trend is expected to continue as pharmaceutical companies spend on R&D to generate more new oral medicines that enhance the quality of life for celiac disease patients. This, in turn, will drive the growth of the market during the forecast period.
Parenteral administration has seen steady expansion in the global celiac disease drugs market due to the limited effectiveness of oral therapies for this autoimmune disease. Celiac disease, which is characterized by gluten intolerance, necessitates precision medicine delivery to treat symptoms and prevent complications. Further, to suppress inflammation during the acute phases of the condition, corticosteroids such as prednisone can be injected intravenously or intramuscularly. The increased awareness of celiac disease and the development of novel parenteral therapeutics are expected to fuel additional growth in this market segment. Due to this growth trend, the market is expected to witness growth during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 58% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In 2022, North America held the highest share of the global celiac disease drugs market. The market is expected to grow due to factors such as the rising prevalence of celiac diseases, growing awareness of celiac diseases, the presence of key companies, and a strong pipeline of drugs in the region. Due to the increase in the consumption of gluten-containing food, the prevalence of the disease is growing in the US. The consumption of beer and fast food is increasing in the region, which is a major risk factor for celiac disease.
For instance, around 63% of American adults drink alcohol, and their favored beverage is beer. Around 42% of American drinkers prefer beer and its high consumption is a major risk factor for celiac disease. Also, fast-food consumption is growing in the region due to busy work life and a growing preference for ready-to-eat food. Therefore, the high consumption of gluten-containing food and the growing prevalence of celiac diseases are anticipated to drive the growth of the regional market during the forecast period.
In 2020, the outbreak of the COVID-19 pandemic altered the celiac disease drugs market in North America. Further, the introduction of COVID-19 vaccinations in 2021 provides a more stable environment for the celiac disease drug market in North America. Patients sought prompt diagnosis and treatment as their trust in healthcare systems recovered, favorably boosting drug sales. Further, the celiac disease drug market in North America is expected to grow steadily. Therefore, advances in diagnostic tools and treatments, such as gluten-targeted therapy, are anticipated to drive the growth of the regional market during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Adaptive Biotechnologies Corp. - The company offers celiac disease drugs such as Immunoseq dx, Pairseq and Trutcr.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Higher consumption of gluten-containing food is notably driving the market growth. Due to the high consumption of food containing gluten, celiac disease is characterized by an increase in gluten deposition in the body. Pizza, cake, soups, beer, bread, cookies, pasta, and burgers are some of the widely consumed foods that contain gluten. Globally, the consumption of fast food such as pizza and burgers is increasing. For instance, in the US, the consumption of pizza is at a moderate level.
Moreover, the rise in per capita income, changing lifestyle, addiction toward junk food and beverages, and the introduction of ready-to-use packaged eateries have contributed to the upsurge in the consumption of gluten-containing food. Thus, The chances of acquiring celiac disease are also high due to the high consumption of gluten-containing food. These factors are anticipated to fuel the growth of the market during the forecast period.
Increasing promising developments in celiac treatment is an emerging trend shaping the market growth. Nowadays, for celiac disease management, there is no approved drug indicated. However, the current pipeline is robust. Such drugs are anticipated to be approved and launched during the forecast period. With higher impacts, these drugs will change market dynamics.
Moreover, these drugs act by various mechanisms (s) and with various approaches to treating celiac diseases at multiple targets. These drugs will drive the market and change the current market dynamics during the forecast period.
The complexity of the disease is a significant challenge hindering market growth. Celiac disease is associated with a variety of symptoms and these symptoms are associated with various organs throughout the body. These symptoms make the disease more intricate and, therefore, difficult to manage. Similarly, celiac disease is a multisystem disorder that impacts various human organs.
Moreover, they may face immune-mediated disorders while consuming gluten in cases where celiac disease is hereditary, and celiac disease drugs may not be effective in such cases. Therefore, such factors may adversely influence the growth of the market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Celiac Diseases Drugs Market Customer Landscape
The celiac diseases drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
|
Celiac Diseases Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
155 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 17.01% |
|
Market growth 2023-2027 |
USD 701.59 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
15.85 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 58% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
9 Meters Biopharma Inc., Adaptive Biotechnologies Corp., Almirall SA, Amgen Inc., AMYRA Biotech AG, Artielle Immunotherapeutics Inc, Avaxia Biologics Inc., BioLineRx Ltd., Bristol Myers Squibb Co., Calypso Biotech BV, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., ImmunogenX Inc., Johnson and Johnson, Precigen Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Vactech Oy, and Zedira GmbH |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
